|
Volumn 87, Issue 6, 2010, Pages 645-647
|
Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIEMETIC AGENT;
CERIVASTATIN;
ROFECOXIB;
ROSIGLITAZONE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
COURT;
DEATH;
DEFIBRILLATOR;
DRUG APPROVAL;
DRUG INDUSTRY;
ELECTRIC SHOCK;
FOOD AND DRUG ADMINISTRATION;
FRACTURE;
GANGRENE;
HUMAN;
LAW SUIT;
LEGAL LIABILITY;
MEDICAL INSTRUMENTATION;
MIGRAINE;
PATIENT SAFETY;
PRESCRIPTION;
PRIORITY JOURNAL;
RESPONSIBILITY;
RHABDOMYOLYSIS;
SAFETY;
SHORT SURVEY;
SIDE EFFECT;
DEVICE APPROVAL;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG LABELING;
DRUG TOXICITY;
EQUIPMENT AND SUPPLIES;
EQUIPMENT SAFETY;
HUMANS;
INDUSTRY;
LIABILITY, LEGAL;
PRODUCT LABELING;
SUPREME COURT DECISIONS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 77952558872
PISSN: 00099236
EISSN: 15326535
Source Type: Journal
DOI: 10.1038/clpt.2009.213 Document Type: Short Survey |
Times cited : (10)
|
References (11)
|